Dr. Mohamad A. Cherry, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 415
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NJ license 25MA10222700 -
Internal Medicine Physician
OK license 24879
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Morristown Medical Center Morristown, NJ
- Overlook Medical Center Summit, NJ
- Chilton Medical Center Pompton Plains, NJ
- Newton Medical Center Newton, NJ
- Ahs Hospital Corp Hackettstown, NJ
Medical groups
- Practice Associates Medical Group (1,408 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 415
- Services billed
- 3,292
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 587 | 207 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 584 | 95 |
| Insertion of needle into vein for collection of blood sample | 509 | 176 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 500 | 174 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 205 | 85 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 107 | 82 |
| Established patient office or other outpatient visit, 40-54 minutes | 96 | 61 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 39 | 29 |
| New patient office or other outpatient visit, 60-74 minutes | 31 | 31 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 28 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Morristown, NJ | 33 |
| Prednisone Other prescribers in Morristown, NJ | 22 |
| Xarelto (rivaroxaban) Other prescribers in Morristown, NJ | 22 |
| Hydroxyurea Other prescribers in Morristown, NJ | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 30 companies reported 197 payments worth $35,380 in total to this clinician.
| Genzyme Corporation | $15,314 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $11,493 |
| Syndax Pharmaceuticals, Inc. | $3,720 |
| Pfizer Inc. | $2,336 |
| Daiichi Sankyo Inc. | $485 |
| AstraZeneca Pharmaceuticals LP | $236 |
| GlaxoSmithKline, LLC. | $182 |
| Janssen Biotech, Inc. | $172 |
| Compensation for services other than consulting (speaking, faculty) | $19,815 |
|---|---|
| Consulting Fee | $10,154 |
| Food and Beverage | $3,580 |
| Travel and Lodging | $1,815 |
| Education | $17.16 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $8,238 |
| E.r. Squibb & Sons, L.l.c. Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $3,640 |
| E.r. Squibb & Sons, L.l.c. Aug 27, 2025 | Consulting Fee | $3,343 |
| Syndax Pharmaceuticals, Inc. Sep 13, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $3,301 |
| Genzyme Corporation Oct 9, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $2,966 |
| E.r. Squibb & Sons, L.l.c. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $2,664 |
| Genzyme Corporation Apr 4, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $2,307 |
| Pfizer Inc. Nov 10, 2025 | Consulting Fee ELREXFIO · ONCOLOGY | $2,100 |
| E.r. Squibb & Sons, L.l.c. May 19, 2025 | Consulting Fee | $955 |
| Genzyme Corporation Oct 8, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Oklahoma City, OK · in-kind | $881 |
All 16 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Nov 10, 2025 | Consulting Fee ELREXFIO · ONCOLOGY | $2,100 |
| Genzyme Corporation Oct 9, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $2,966 |
| Genzyme Corporation Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $8,238 |
| Genzyme Corporation Oct 8, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Oklahoma City, OK · in-kind | $881 |
| Genzyme Corporation Oct 8, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Oklahoma City, OK | $437 |
| Genzyme Corporation Oct 8, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Oklahoma City, OK | $219 |
| Genzyme Corporation Oct 8, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Oklahoma City, OK | $20.00 |
| Syndax Pharmaceuticals, Inc. Sep 13, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $3,301 |
| Syndax Pharmaceuticals, Inc. Sep 13, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to NEW YORK, NY · in-kind | $257 |
| E.r. Squibb & Sons, L.l.c. Aug 27, 2025 | Consulting Fee | $3,343 |
| E.r. Squibb & Sons, L.l.c. May 20, 2025 | Consulting Fee | $455 |
| E.r. Squibb & Sons, L.l.c. May 19, 2025 | Consulting Fee | $955 |
| Pfizer Inc. May 7, 2025 | Education ELREXFIO · ONCOLOGY · in-kind | $17.16 |
| E.r. Squibb & Sons, L.l.c. Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $3,640 |
| Genzyme Corporation Apr 4, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $2,307 |
| E.r. Squibb & Sons, L.l.c. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $2,664 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 4 companies. The companies reported $274,991 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with …
Celgene Corporation - A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
Celgene Corporation · Active, not recruiting · NCT04245839 - A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT06045689 - A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with …
E.r. Squibb & Sons, L.l.c. - An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Celgene Corporation - A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc. · Recruiting · NCT04988555 - A phase 3 openlabel study of elranatamab monotherapy versus elotuzumab pomalidomide dexamethasone epd or pomalidomide bortezomib dexamethasone pvd or carfilzomib dexamethasone kd in participants with relapsedrefractor…
Pfizer Inc. - Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Celgene Corporation · Recruiting · NCT03435796 - A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Celgene Corporation · Active, not recruiting · NCT05827016
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.